Top Markets
#1 TENDIES TENDIES +59.67%
#2 Threshold Network Threshold Network +58.79%
#3 Cash Cat Cash Cat +21.23%
#4 OSK OSK +15.93%
#5 Magma Finance Magma Finance +13.61%
#6 Falcon Finance Falcon Finance +12.83%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Kite Kite +11.86%
#9 Maple Finance Maple Finance +11.45%
#10 Asteroid Shiba Asteroid Shiba +9.44%
Coin of the day
TENDIES TENDIES
Settings
Language
ENGLISH
Currency
USD
Theme
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Rank in Stocks #17261
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Share Price
$0.8502
Last synced: 2026-09-01
Market Cap
$250.47M
Change (1 day)
-10.96%
Change (1 year)
-17.46%
Country
US
Trade Invivyd, Inc. (IVVD)

Category

Healthcare
Revenue for Invivyd, Inc. (IVVD)
Revenue in Sep 2026 TTM: 0
According to Invivyd, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Invivyd, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH